ADCT
NYSE · Biotechnology
Adc Therapeutics Sa
$3.83
+0.05 (+1.32%)
Open$3.78
Previous Close$3.78
Day High$3.85
Day Low$3.72
52W High$4.98
52W Low$1.23
Volume—
Avg Volume1.32M
Market Cap476.97M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+411.0% upside
Current
$3.83
$3.83
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 79.74M | 109.37M | 66.42M |
| Net Income | -139,777,433 | -172,541,063 | 9.87M |
| Profit Margin | -175.3% | -166.5% | 14.9% |
| EBITDA | -95,468,086 | -124,392,650 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | -27.1% | -27.1% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |